ES2192621T3 - Sales de derivados de quinoleina como antagonistas de nk3. - Google Patents

Sales de derivados de quinoleina como antagonistas de nk3.

Info

Publication number
ES2192621T3
ES2192621T3 ES96941026T ES96941026T ES2192621T3 ES 2192621 T3 ES2192621 T3 ES 2192621T3 ES 96941026 T ES96941026 T ES 96941026T ES 96941026 T ES96941026 T ES 96941026T ES 2192621 T3 ES2192621 T3 ES 2192621T3
Authority
ES
Spain
Prior art keywords
quinoleine
antagonists
derivatives
salts
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96941026T
Other languages
English (en)
Inventor
Giuseppe Arnaldo Mari Giardina
Carlo Farina
Mario Grugni
Luca Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of ES2192621T3 publication Critical patent/ES2192621T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN COMPUESTO DE FORMULA (I) O A UN SOLVATO DEL MISMO, CARACTERIZADO PORQUE DICHA SAL COMPRENDE UN COMPUESTO DE FORMULA (I) EN FORMA ANIONICA Y UN CATION DE SALIFICACION. SE DESCRIBE ASIMISMO UN PROCEDIMIENTO DE PREPARACION DE DICHO COMPUESTO, UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE Y LA UTILIZACION DE LA MISMA EN MEDICINA.
ES96941026T 1995-11-24 1996-11-22 Sales de derivados de quinoleina como antagonistas de nk3. Expired - Lifetime ES2192621T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9524137.8A GB9524137D0 (en) 1995-11-24 1995-11-24 Novel compounds

Publications (1)

Publication Number Publication Date
ES2192621T3 true ES2192621T3 (es) 2003-10-16

Family

ID=10784449

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96941026T Expired - Lifetime ES2192621T3 (es) 1995-11-24 1996-11-22 Sales de derivados de quinoleina como antagonistas de nk3.

Country Status (23)

Country Link
US (3) US6355654B1 (es)
EP (1) EP0876348B1 (es)
JP (1) JP4377454B2 (es)
KR (1) KR19990071599A (es)
CN (1) CN1207728A (es)
AR (1) AR004970A1 (es)
AT (1) ATE233243T1 (es)
AU (1) AU722451B2 (es)
BR (1) BR9611729A (es)
CA (1) CA2238312A1 (es)
CZ (1) CZ158198A3 (es)
DE (1) DE69626416T2 (es)
ES (1) ES2192621T3 (es)
GB (1) GB9524137D0 (es)
HU (1) HUP9903584A3 (es)
IL (1) IL124352A0 (es)
MX (1) MX9804106A (es)
NO (1) NO310866B1 (es)
NZ (1) NZ323389A (es)
PL (1) PL326927A1 (es)
TR (1) TR199800925T2 (es)
WO (1) WO1997019928A1 (es)
ZA (1) ZA969812B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
CA2611060A1 (en) * 2005-06-03 2006-12-07 R. Thomas Simpson Quinoline derivatives as nk3 antagonists
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (en) * 2005-08-02 2010-08-18 Glaxosmithkline Llc PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES
US20080280949A1 (en) * 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
JP2009508944A (ja) * 2005-09-21 2009-03-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体リガンドとしてのｎ−オキソ複素環及びｎ−オキソ−アルキルキノリン−４−カルボキシアミド類
AR057130A1 (es) * 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
WO2007086799A1 (en) * 2006-01-27 2007-08-02 Astrazeneca Ab Amide substituted quinolines
FR2979173B1 (fr) * 2011-08-19 2013-08-16 St Microelectronics Grenoble 2 Commutateur analogique basse tension
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273959T1 (de) * 1994-05-27 2004-09-15 Glaxosmithkline Spa Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
AU1031997A (en) 1997-06-19
TR199800925T2 (xx) 2001-05-21
CA2238312A1 (en) 1997-06-05
MX9804106A (es) 1998-09-30
BR9611729A (pt) 1999-04-06
ZA969812B (en) 1998-05-22
AR004970A1 (es) 1999-04-07
WO1997019928A1 (en) 1997-06-05
US20020156097A1 (en) 2002-10-24
EP0876348A1 (en) 1998-11-11
EP0876348B1 (en) 2003-02-26
NO982332D0 (no) 1998-05-22
JP4377454B2 (ja) 2009-12-02
GB9524137D0 (en) 1996-01-24
DE69626416T2 (de) 2003-12-24
US6432977B1 (en) 2002-08-13
US20020077335A1 (en) 2002-06-20
NZ323389A (en) 2000-02-28
US6355654B1 (en) 2002-03-12
HUP9903584A2 (hu) 2000-02-28
CZ158198A3 (cs) 1998-10-14
JP2000500770A (ja) 2000-01-25
IL124352A0 (en) 1998-12-06
NO982332L (no) 1998-05-22
KR19990071599A (ko) 1999-09-27
NO310866B1 (no) 2001-09-10
ATE233243T1 (de) 2003-03-15
CN1207728A (zh) 1999-02-10
AU722451B2 (en) 2000-08-03
DE69626416D1 (de) 2003-04-03
PL326927A1 (en) 1998-11-09
HUP9903584A3 (en) 2001-10-29

Similar Documents

Publication Publication Date Title
ES2192621T3 (es) Sales de derivados de quinoleina como antagonistas de nk3.
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
ECSP034436A (es) Sales de valsartan
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
SE9904505D0 (sv) Novel compounds
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
AR003121A1 (es) Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades
EA199700160A1 (ru) Производные индола в качестве антагонистов eaa
ES2156255T3 (es) Procedimiento para preparar antagonistas del receptor de fibrinogeno.
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
ES2134459T3 (es) Indeno(1,2-e)pirazina-4-onas, su preparacion y los medicamentos que les contienen.
BR0015333A (pt) Derivados de isoxazol como inibidores de fosfodiesterase vii
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE8405588D0 (sv) New compounds
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.
EP0758312A4 (en) SUBSTITUTED CONDENSED AND BRIDGED BICYCLIC COMPOUNDS AS THERAPEUTIC AGENTS
SE9103776D0 (sv) New compounds
AR008236A1 (es) Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica
SE0102058D0 (sv) New Salts II
MX9603343A (es) Antagonistas del receptor endotelial, procedimiento para preparar dichos compuestos y preparaciones farmaceuticas que los contienen.
BR0113752A (pt) Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase